Literature DB >> 19549893

Evaluation of the 8q24 prostate cancer risk locus and MYC expression.

Mark M Pomerantz1, Christine A Beckwith, Meredith M Regan, Stacia K Wyman, Gyorgy Petrovics, Yongmei Chen, Dorota J Hawksworth, Fredrick R Schumacher, Lorelei Mucci, Kathryn L Penney, Meir J Stampfer, Jennifer A Chan, Kristin G Ardlie, Brian R Fritz, Rachael K Parkin, Daniel W Lin, Michelle Dyke, Paula Herman, Steve Lee, William K Oh, Philip W Kantoff, Muneesh Tewari, David G McLeod, Shiv Srivastava, Matthew L Freedman.   

Abstract

Polymorphisms at 8q24 are robustly associated with prostate cancer risk. The risk variants are located in nonprotein coding regions and their mechanism has not been fully elucidated. To further dissect the function of this locus, we tested two hypotheses: (a) unannotated microRNAs (miRNA) are transcribed in the region, and (b) this region is a cis-acting enhancer. Using next generation sequencing, 8q24 risk regions were interrogated for known and novel miRNAs in histologically normal radical prostatectomy tissue. We also evaluated the association between the risk variants and transcript levels of multiple genes, focusing on the proto-oncogene, MYC. RNA expression was measured in histologically normal and tumor tissue from 280 prostatectomy specimens (from 234 European American and 46 African American patients), and paired germline DNA from each individual was genotyped for six 8q24 risk single nucleotide polymorphisms. No evidence was found for significant miRNA transcription within 8q24 prostate cancer risk loci. Likewise, no convincing association between RNA expression and risk allele status was detected in either histologically normal or tumor tissue. To our knowledge, this is one of the first and largest studies to directly assess miRNA in this region and to systematically measure MYC expression levels in prostate tissue in relation to inherited risk variants. These data will help to direct the future study of this risk locus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549893      PMCID: PMC2884104          DOI: 10.1158/0008-5472.CAN-09-0387

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.

Authors:  R Buttyan; I S Sawczuk; M C Benson; J D Siegal; C A Olsson
Journal:  Prostate       Date:  1987       Impact factor: 4.104

2.  The PVT gene frequently amplifies with MYC in tumor cells.

Authors:  E Shtivelman; J M Bishop
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

3.  TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression.

Authors:  Achim Weber; Juhong Liu; Irene Collins; David Levens
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

4.  Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients.

Authors:  Gyorgy Petrovics; Wei Zhang; Mazen Makarem; Jesse P Street; Roger Connelly; Leon Sun; Isabell A Sesterhenn; Vasantha Srikantan; Judd W Moul; Shiv Srivastava
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

5.  The role of metastasis-associated protein 1 in prostate cancer progression.

Authors:  Matthias D Hofer; Rainer Kuefer; Sooryanarayana Varambally; Haojie Li; Jing Ma; Geoffrey I Shapiro; Juergen E Gschwend; Richard E Hautmann; Martin G Sanda; Klaudia Giehl; Andre Menke; Arul M Chinnaiyan; Mark A Rubin
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

6.  Distinct thresholds govern Myc's biological output in vivo.

Authors:  Daniel J Murphy; Melissa R Junttila; Laurent Pouyet; Anthony Karnezis; Ksenya Shchors; Duyen A Bui; Lamorna Brown-Swigart; Leisa Johnson; Gerard I Evan
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

7.  Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

Authors:  Christopher L Amling; Robert H Riffenburgh; Leon Sun; Judd W Moul; Raymond S Lance; Leo Kusuda; Wade J Sexton; Douglas W Soderdahl; Timothy F Donahue; John P Foley; Andrew K Chung; David G McLeod
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

8.  Immortalization of primary human prostate epithelial cells by c-Myc.

Authors:  Jesús Gil; Preeti Kerai; Matilde Lleonart; David Bernard; Juan Cruz Cigudosa; Gordon Peters; Amancio Carnero; David Beach
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 13.312

9.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

10.  Developmental context determines latency of MYC-induced tumorigenesis.

Authors:  Shelly Beer; Anders Zetterberg; Rebecca A Ihrie; Ryan A McTaggart; Qiwei Yang; Nicole Bradon; Constadina Arvanitis; Laura D Attardi; Sandy Feng; Boris Ruebner; Robert D Cardiff; Dean W Felsher
Journal:  PLoS Biol       Date:  2004-09-28       Impact factor: 8.029

View more
  68 in total

1.  Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection.

Authors:  Lucinda Hughes; Fang Zhu; Eric Ross; Laura Gross; Robert G Uzzo; David Y T Chen; Rosalia Viterbo; Timothy R Rebbeck; Veda N Giri
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-05       Impact factor: 4.254

2.  Genetic variation at chromosome 8q24 in osteosarcoma cases and controls.

Authors:  Lisa Mirabello; Sonja I Berndt; Guillermo F Seratti; Laurie Burdett; Meredith Yeager; Salma Chowdhury; Kedest Teshome; Arinze Uzoka; Chester Douglass; Richard B Hayes; Robert N Hoover; Sharon A Savage
Journal:  Carcinogenesis       Date:  2010-06-07       Impact factor: 4.944

3.  In vivo exploration of the functional activity of the non-coding 8q24 prostate cancer risk locus.

Authors:  Dolores J Lamb; Mounia Tannour-Louet
Journal:  Asian J Androl       Date:  2010-09-06       Impact factor: 3.285

4.  8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC.

Authors:  Nasim Ahmadiyeh; Mark M Pomerantz; Chiara Grisanzio; Paula Herman; Li Jia; Vanessa Almendro; Housheng Hansen He; Myles Brown; X Shirley Liu; Matt Davis; Jennifer L Caswell; Christine A Beckwith; Adam Hills; Laura Macconaill; Gerhard A Coetzee; Meredith M Regan; Matthew L Freedman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-07       Impact factor: 11.205

5.  An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer.

Authors:  Nora F Wasserman; Ivy Aneas; Marcelo A Nobrega
Journal:  Genome Res       Date:  2010-07-13       Impact factor: 9.043

6.  Pesticide use modifies the association between genetic variants on chromosome 8q24 and prostate cancer.

Authors:  Stella Koutros; Laura E Beane Freeman; Sonja I Berndt; Gabriella Andreotti; Jay H Lubin; Dale P Sandler; Jane A Hoppin; Kai Yu; Qizhai Li; Laura A Burdette; Jeffrey Yuenger; Meredith Yeager; Michael C R Alavanja
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

7.  Multiple loci on 8q24 associated with prostate cancer susceptibility.

Authors:  Ali Amin Al Olama; Zsofia Kote-Jarai; Graham G Giles; Michelle Guy; Jonathan Morrison; Gianluca Severi; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Sameer Jhavar; Ed Saunders; John L Hopper; Melissa C Southey; Kenneth R Muir; Dallas R English; David P Dearnaley; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Rosemary A Wilkinson; Emma Sawyer; Artitaya Lophatananon; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Colin Cooper; Jenny L Donovan; Freddie C Hamdy; David E Neal; Rosalind A Eeles; Douglas F Easton
Journal:  Nat Genet       Date:  2009-09-20       Impact factor: 38.330

8.  A beta-catenin/TCF-coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers.

Authors:  Gregory S Yochum; Colette M Sherrick; Mary Macpartlin; Richard H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

9.  An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility.

Authors:  Joan P Breyer; Daniel C Dorset; Travis A Clark; Kevin M Bradley; Tiina A Wahlfors; Kate M McReynolds; William H Maynard; Sam S Chang; Michael S Cookson; Joseph A Smith; Johanna Schleutker; William D Dupont; Jeffrey R Smith
Journal:  Am J Hum Genet       Date:  2014-02-27       Impact factor: 11.025

10.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.